Rheumatology
M-A | Efficacy and safety of duloxetine in chronic musculoskeletal pain
5 Jun, 2023 | 13:09h | UTC
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050
2 Jun, 2023 | 12:34h | UTCEditorial: The global epidemic of low back pain – The Lancet Rheumatology
News Releases:
Commentary on Twitter
NEW—GBD 2021 data published in @TheLancetRheum finds low back pain is the leading cause of disability globally. #LowBackPain affects 619 million individuals (1 out of every 13 people). More women across all age groups suffered from low back pain than men.https://t.co/A2RoU9hn9p pic.twitter.com/vhXwcVh1e7
— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) May 22, 2023
ACR Guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis
2 Jun, 2023 | 12:33h | UTCNews Release: New Guideline Introduces Recommendations for Integrative Approach to RA Treatment – American College of Rheumatology
Consensus Document | Diagnosis and treatment of lupus nephritis
2 Jun, 2023 | 12:26h | UTC
Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care
2 Jun, 2023 | 12:18h | UTC
SR | Biomarkers for myalgic encephalomyelitis/chronic fatigue syndrome
1 Jun, 2023 | 12:06h | UTC
Proposing a new five-type classification for glomerulonephritis based on pathogenesis, activity, and chronicity
31 May, 2023 | 14:11h | UTC
Commentary on Twitter
The five types of glomerulonephritis classified by pathogenesis, activity & chronicity (GN-AC)
?https://t.co/NYKBde4L1I
?The major entities of GN
?Autoantigens in autoimmune GN
?Multilevel diagnostic algorithm of GN
?Proposed GN-AC classification & reporting system for GN pic.twitter.com/shmLLhCfJk— NDT (@NDTsocial) May 24, 2023
Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis
24 May, 2023 | 13:16h | UTCEvidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis – Nature Reviews Rheumatology (if the link is paywalled, try this one)
Related: 2022 ACR/EULAR Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis.
Commentary on Twitter
New content online! Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis https://t.co/iBNSi55JfK pic.twitter.com/Wh71oHGXOL
— NatRevRheumatol (@NatRevRheumatol) May 9, 2023
Review | Update in musculoskeletal pain in older adults with a focus on osteoarthritis-related pain
24 May, 2023 | 13:09h | UTC
Phase 2 RCT | Peresolimab outperforms placebo in patients with moderate-to-severe rheumatoid arthritis
24 May, 2023 | 13:07h | UTCA Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Peresolimab Demonstrates Efficacy in Treating Patients With Rheumatoid Arthritis – HCP Live
Commentary on Twitter
Peresolimab showed efficacy in a phase 2a trial in patients with rheumatoid arthritis. These results provide evidence that stimulation of the PD-1 receptor has potential efficacy in the treatment of rheumatoid arthritis. https://t.co/2MkxLBrKTf
— NEJM (@NEJM) May 20, 2023
M-A | Limited evidence for safety and effectiveness of most antidepressants in chronic pain management
18 May, 2023 | 13:50h | UTC
Cohort Study | Patients with joint hypermobility at greater risk of second ACL injury post-surgery within a year of return to sport
18 May, 2023 | 13:33h | UTCRCT | Colchicine ineffective for pain relief in hand osteoarthritis patients
16 May, 2023 | 14:42h | UTCColchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial – The Lancet Rheumatology (link to abstract – $ for full-text)
Commentary: Colchicine Does Not Relieve OA-Related Hand Pain Compared With Placebo – DocWireNews
Commentary on Twitter
NEW RESEARCH—@AnnaDossing and colleagues report the results of the COLOR trial; #colchicine twice a day did not relieve #pain vs placebo in people with hand #osteoarthritis https://t.co/LfKTwVONGM pic.twitter.com/jTBh076LZ6
— The Lancet Rheumatology (@TheLancetRheum) April 5, 2023
Canadian Task Force advises fragility fracture screening for women over 65, but not for men or younger women
15 May, 2023 | 13:23h | UTCRelated USPSTF Statement: Screening Osteoporosis to Prevent Fractures
Therapeutic plasma exchange: Core curriculum 2023
15 May, 2023 | 13:14h | UTCTherapeutic Plasma Exchange: Core Curriculum 2023 – American Journal of Kidney Diseases
Commentary on Twitter
Therapeutic Plasma Exchange: Core Curriculum 2023 https://t.co/6IoHXeAzyO (FREE)@Elena_Cervants @JohnSperati pic.twitter.com/3OVgAhXjCv
— AJKD (@AJKDonline) May 7, 2023
Cutaneous Lupus Erythematosus | An update on pathogenesis and future therapeutic directions
12 May, 2023 | 13:28h | UTC
M-A | Surgical interventions for symptomatic knee osteoarthritis
12 May, 2023 | 13:26h | UTC
RCT | Cognitive functional therapy with or without biofeedback outperforms usual care for chronic low back pain relief
10 May, 2023 | 15:58h | UTCCognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial – The Lancet (link to abstract – $ for full-text)
News Release: Fresh hope for Australians living with chronic back pain – Curtin University
Proposal of a new diagnostic algorithm for adult-onset Still’s disease
9 May, 2023 | 14:41h | UTCProposal of a new diagnostic algorithm for adult-onset Still’s disease – Clinical Rheumatology
Commentary on Twitter
Multicenter study of 80 AOSD & 60 controls used to develop AOSD criteria:
– 3 pts rash
– 3pts fever ≥ 39C
– 2 pts pharyngitis
– 2 pts arthritis
– 2 pts NLR ≥ 4
– 1 pt glycosyl ferritin ≤ 20%
7 pts = Dx (sens 92.5%) vs Yamaguchi(79%), Fautrel (76%) https://t.co/Amew1RHaA1 pic.twitter.com/dnJ6zVyfOW— Dr. John Cush (@RheumNow) February 8, 2023
Cohort Study | Autoimmune disorders’ incidence, prevalence & co-occurrence by age, sex, and socioeconomic status
8 May, 2023 | 13:14h | UTCIncidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK – The Lancet (free for a limited period)
Commentary from the author on Twitter (thread – click for more)
Our latest research is out in @TheLancet today
We sought to answer:
1. Are autoimmune diseases on the rise as has been suggested?
2. Can we identify clues as to their causes (genetic or environmental)?
3. Do different autoimmune diseases cluster together & what might this mean? pic.twitter.com/noCpPpo8FU— Nathalie Conrad (@nathalie_conrad) May 6, 2023
SR | What Is the efficacy of intra-articular injections in the treatment of ankle osteoarthritis
8 May, 2023 | 12:48h | UTC
Treating long-lasting low back pain without surgery: the latest evidence
4 May, 2023 | 13:40h | UTCTreating long-lasting low back pain without surgery: the latest evidence – Evidently Cochrane
M-A | Efficacy of osteoporosis interventions on fracture prevention in postmenopausal women
3 May, 2023 | 15:37h | UTC
Guideline | Management of systemic lupus erythematosus
12 Apr, 2023 | 13:16h | UTC
Pharmacological treatments for low back pain in adults: an overview of Cochrane Reviews
11 Apr, 2023 | 14:39h | UTCRelated:
SR | Nonopioid pharmacological management of acute low back pain
M-A | Limited evidence for analgesic effectiveness in acute low back pain treatment
M-A: Effectiveness of treatments for acute and subacute mechanical non-specific low back pain
Guideline Interventions for the management of acute and chronic low back pain.
M-A: Little benefit from muscle relaxants for adults with non-specific low back pain.